ClinicalTrials.gg
RecruitingNCT07856368fuNEEGUpdated Oct 2, 2026

Neuronavigated rTMS for Treatment-Resistant Auditory Hallucinations

An interventional study of Neuronavigated repetitive transcranial magnetic stimulation (rTMS) and Sham repetitive transcranial magnetic stimulation (rTMS) in Schizophrenia and Auditory Verbal Hallucinations, sponsored by Psychiatric University Hospital, Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Psychiatric University Hospital, Zurich · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2026, registered Sep 2026).
  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Schizophrenia with a site in Switzerland — 6 open to participants now, 6 under way, 1 of them phase 3. Schizophrenia · Switzerland.

Planned enrollment
21st of 27
40 · median 100
Started
2026
the only one that year
No phase
17 of 30
5 open now
Registered
30th of 30
by date
Lead sponsor
5 of 30
Psychiatric University Hospital, Zurich

Among the 30 studies in Schizophrenia with a site in Switzerland, this one is the 21st largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2026, is one of 17 with no phase, and was the 30th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 30 studies in Schizophrenia with a site in Switzerland are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Schizophrenia with a site in Switzerland, or all of them as a file.
02

Study summary

Auditory verbal hallucinations (AVH), such as hearing voices in the absence of an external sound source, are a common and distressing symptom of schizophrenia. In some patients, hallucinations persist despite treatment with antipsychotic medication. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that may reduce auditory hallucinations by decreasing activity in brain regions involved in auditory and language processing.

This randomized, double-blind, sham-controlled study will investigate whether individualized, neuronavigated inhibitory rTMS can reduce persistent auditory verbal hallucinations. Forty adults with medication-resistant auditory hallucinations will be randomly assigned to receive either active rTMS or sham stimulation.

For each participant, the stimulation target in the primary auditory cortex will be individually identified using electroencephalography (EEG), acoustic evoked potentials, and magnetic resonance imaging (MRI)-based neuronavigation. Participants will receive two rTMS sessions per day for five consecutive days. The severity of auditory hallucinations will be assessed before and after treatment and at a 28-day follow-up.

The study will also investigate whether treatment is associated with changes in brain activity and functional connectivity measured by EEG, including changes in the P300 event-related potential.

03

Conditions studied

  • Schizophrenia
  • Auditory Verbal Hallucinations

Keywords

  • Auditory Verbal Hallucinations
  • Treatment-Resistant Hallucinations
  • Repetitive Transcranial Magnetic Stimulation
  • rTMS
  • Neuronavigation
  • Electroencephalography
  • EEG
  • Auditory Evoked Potentials
  • Functional Connectivity
  • P300
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written provided prior to participation
  • Age 18 to 65 years
  • Medication-resistant auditory hallucinations, defined as:

    • At least two adequate trials of antipsychotic medication
    • At least one of these trials with an atypical antipsychotic medication
    • At least five episodes of auditory hallucinations per day during the preceding month
    • Stable antipsychotic medication for at least 6 weeks
  • Current treatment at the Psychiatric University Hospital Zurich (PUK), either in an outpatient clinic, day clinic, or inpatient ward
  • Sufficient knowledge of German to understand the study procedures and assessments
  • Ability to follow study procedures

Exclusion criteria

Exclusion Criteria:

  • to TMS treatment, including cochlear implants, metallic devices close to the TMS coil, history of stroke, head injury, or seizures/epilepsy
  • History of epileptic convulsive seizures or epileptiform potentials in previous EEG examinations
  • TMS treatment within the 3 months preceding study inclusion
  • Known severe or severe adverse reaction to TMS
  • Pregnancy or breastfeeding
  • Intention to become pregnant during the study
  • Major somatic comorbidities, such as renal failure, hepatic dysfunction, heart failure, or cardiovascular disease
  • Current treatment with any drug that lowers the seizure threshold
  • Known or suspected non-compliance, drug abuse, or alcohol abuse
  • Vulnerable subjects (children, pregnant women, elderly persons)
  • Inability to follow study procedures, for example due to language problems, psychological disorder, dementia, or other conditions interfering with participation
  • Participation in another study involving treatment within the 30 days preceding study inclusion or during the present study
  • Current electroconvulsive therapy (ECT)
  • Previous enrollment in the present study
  • Investigator, family member of the investigator, employee, or other dependent person
  • Contraindications or limitations related to the medical device as specified in the instructions for use
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Active rTMS

    Participants receive individualized, neuronavigated inhibitory rTMS targeting the primary auditory cortex. The stimulation target is individually determined using EEG-based auditory evoked potentials and MRI-based neuronavigation. Treatment is administered twice daily for five consecutive days.

    Device: Neuronavigated repetitive transcranial magnetic stimulation (rTMS)

  • Sham comparator
    Sham rTMS

    Participants undergo the same treatment schedule and neuronavigation procedures as the active rTMS group using a sham coil that is visually and acoustically similar to the active coil but does not deliver active magnetic stimulation.

    Device: Sham repetitive transcranial magnetic stimulation (rTMS)

Interventions

  • DeviceNeuronavigated repetitive transcranial magnetic stimulation (rTMS)

    Individualized neuronavigated inhibitory rTMS is applied to the primary auditory cortex. The individual stimulation target is determined using EEG-based auditory evoked potentials and MRI-based neuronavigation. Stimulation is delivered at 1 Hz on five consecutive days, with a total of 12,000 magnetic pulses administered over the treatment course.

  • DeviceSham repetitive transcranial magnetic stimulation (rTMS)

    Sham stimulation is administered using the same neuronavigation procedures and treatment schedule as active rTMS. A sham coil visually and acoustically resembling the active coil is used but does not deliver active magnetic stimulation.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Auditory Vocal Hallucination Rating Scale (AVHRS) Score Immediately After Treatment

    Change from baseline in auditory hallucination severity assessed with the Auditory Vocal Hallucination Rating Scale (AVHRS), a structured interview assessing multiple characteristics of auditory hallucinations, including frequency, duration, location, loudness, negative content, distress, interference with daily life, perceived control, anxiety, and interference with thinking.

    Time frame: Baseline to immediately after completion of the 5-day treatment period

Secondary outcomes

  1. Change From Baseline in Auditory Vocal Hallucination Rating Scale (AVHRS) Score at Day 28

    Change from baseline in auditory hallucination severity assessed with the Auditory Vocal Hallucination Rating Scale (AVHRS), a structured interview assessing multiple characteristics of auditory hallucinations, including frequency, duration, location, loudness, negative content, distress, interference with daily life, perceived control, anxiety, and interference with thinking.

    Time frame: Baseline to Day 28 after completion of treatment

  2. Change From Baseline in PSYRATS Auditory Hallucinations Subscale Score Immediately After Treatment

    Change from baseline in the Auditory Hallucinations subscale of the Psychotic Symptom Rating Scales (PSYRATS). The subscale consists of 11 items scored from 0 to 4, yielding a total score from 0 to 44. Higher scores indicate greater auditory hallucination severity.

    Time frame: Baseline to immediately after completion of the 5-day treatment period

  3. Change From Baseline in PSYRATS Delusions Subscale Score Immediately After Treatment

    Change from baseline in the Delusions subscale of the Psychotic Symptom Rating Scales (PSYRATS). The subscale consists of 6 items scored from 0 to 4, yielding a total score from 0 to 24. Higher scores indicate greater delusion severity.

    Time frame: Baseline to immediately after completion of the 5-day treatment period

  4. Change From Baseline in PSYRATS Combined Score Immediately After Treatment

    Change from baseline in the combined Psychotic Symptom Rating Scales (PSYRATS) score, calculated as the sum of the Auditory Hallucinations and Delusions subscale scores. The combined score ranges from 0 to 68, with higher scores indicating greater overall psychotic symptom severity.

    Time frame: Baseline to immediately after completion of the 5-day treatment period

  5. Change From Baseline in PSYRATS Auditory Hallucinations Subscale Score at Day 28

    Change from baseline in the Auditory Hallucinations subscale of the Psychotic Symptom Rating Scales (PSYRATS). The subscale consists of 11 items scored from 0 to 4, yielding a total score from 0 to 44. Higher scores indicate greater auditory hallucination severity.

    Time frame: Baseline to Day 28 after completion of treatment

  6. Change From Baseline in PSYRATS Delusions Subscale Score at Day 28

    Change from baseline in the Delusions subscale of the Psychotic Symptom Rating Scales (PSYRATS). The subscale consists of 6 items scored from 0 to 4, yielding a total score from 0 to 24. Higher scores indicate greater delusion severity.

    Time frame: Baseline to Day 28 after completion of treatment

  7. Change From Baseline in PSYRATS Combined Score at Day 28

    Change from baseline in the combined Psychotic Symptom Rating Scales (PSYRATS) score, calculated as the sum of the Auditory Hallucinations and Delusions subscale scores. The combined score ranges from 0 to 68, with higher scores indicating greater overall psychotic symptom severity.

    Time frame: Baseline to Day 28 after completion of treatment

  8. Change From Baseline in Auditory Vocal Hallucination Rating Scale Questionnaire (AVHRS-Q) Total Score Immediately After Treatment

    Change from baseline in the total score of the Auditory Vocal Hallucination Rating Scale Questionnaire (AVHRS-Q), a self-report measure assessing characteristics and severity of auditory vocal hallucinations. Higher scores indicate greater severity of auditory vocal hallucinations.

    Time frame: Baseline to immediately after completion of the 5-day treatment period

  9. Change From Baseline in Auditory Vocal Hallucination Rating Scale Questionnaire (AVHRS-Q) Total Score at Day 28

    Change from baseline in the total score of the Auditory Vocal Hallucination Rating Scale Questionnaire (AVHRS-Q), a self-report measure assessing characteristics and severity of auditory vocal hallucinations. Higher scores indicate greater severity of auditory vocal hallucinations.

    Time frame: Baseline to Day 28 after completion of treatment

  10. Change From Baseline in Self-assessment of Auditory Verbal Hallucinations (SAVH) Total Score Immediately After Treatment

    Change from baseline in the total score of the Self-assessment of Auditory Verbal Hallucinations (SAVH), a 9-item self-report measure assessing auditory verbal hallucinations during the preceding week. Each item is scored from 0 to 5, yielding a total score from 0 to 45. Higher scores indicate greater severity of auditory verbal hallucinations.

    Time frame: Baseline to immediately after completion of the 5-day treatment period

  11. Change From Baseline in Self-assessment of Auditory Verbal Hallucinations (SAVH) Total Score at Day 28

    Change from baseline in the total score of the Self-assessment of Auditory Verbal Hallucinations (SAVH), a 9-item self-report measure assessing auditory verbal hallucinations during the preceding week. Each item is scored from 0 to 5, yielding a total score from 0 to 45. Higher scores indicate greater severity of auditory verbal hallucinations.

    Time frame: Baseline to Day 28 after completion of treatment

  12. Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score Immediately After Treatment

    Change from baseline in illness severity assessed using the Clinical Global Impression-Severity (CGI-S) scale. CGI-S is rated from 1 to 7, with higher scores indicating greater illness severity.

    Time frame: Baseline to immediately after completion of the 5-day treatment period

  13. Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Day 28

    Change from baseline in illness severity assessed using the Clinical Global Impression-Severity (CGI-S) scale. CGI-S is rated from 1 to 7, with higher scores indicating greater illness severity.

    Time frame: Baseline to Day 28 after completion of treatment

  14. Clinical Global Impression-Improvement (CGI-I) Score Immediately After Treatment

    Overall change in clinical condition assessed using the Clinical Global Impression-Improvement (CGI-I) scale. CGI-I is rated from 1 to 7, where 1 indicates very much improved, 4 indicates no change, and 7 indicates very much worse.

    Time frame: Immediately after completion of the 5-day treatment period

  15. Clinical Global Impression-Improvement (CGI-I) Score at Day 28

    Overall change in clinical condition assessed using the Clinical Global Impression-Improvement (CGI-I) scale. CGI-I is rated from 1 to 7, where 1 indicates very much improved, 4 indicates no change, and 7 indicates very much worse.

    Time frame: Day 28 after completion of treatment

  16. Change From Baseline in Auditory P300 Parameters Immediately After Treatment

    Change from baseline in auditory P300 event-related potential parameters measured by EEG during an auditory Oddball paradigm. P300 amplitude and latency elicited by target stimuli will be evaluated and compared between baseline and post-treatment recordings.

    Time frame: Baseline to immediately after completion of the 5-day treatment period

  17. Change From Baseline in Auditory P300 Parameters at Day 28

    Change from baseline in auditory P300 event-related potential parameters measured by EEG during an auditory Oddball paradigm. P300 amplitude and latency elicited by target stimuli will be evaluated and compared between baseline and Day-28 recordings.

    Time frame: Baseline to Day 28 after completion of treatment

  18. Change From Baseline in EEG Functional Connectivity Immediately After Treatment

    Change from baseline in functional brain connectivity assessed using EEG and source localization with low-resolution electromagnetic tomography (LORETA). Treatment-related changes in functional connectivity between cortical brain regions will be evaluated by comparing baseline and post-treatment EEG recordings.

    Time frame: Baseline to immediately after completion of the 5-day treatment period

  19. Change From Baseline in EEG Functional Connectivity at Day 28

    Change from baseline in functional brain connectivity assessed using EEG and source localization with low-resolution electromagnetic tomography (LORETA). Treatment-related changes in functional connectivity between cortical brain regions will be evaluated by comparing baseline and Day-28 EEG recordings.

    Time frame: Baseline to Day 28 after completion of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data are not planned to be made publicly available. Potential reuse of pseudonymized data may be considered in accordance with participant consent and applicable ethical and data protection requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Nov 2028, 29 months after the start.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 29 months is below that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Oct 2, 2026
StartActual
Jun 11, 2026
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856368
Lead sponsor
Psychiatric University Hospital, Zurich
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Jun 11, 2026
Primary completion
Nov 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Tobias Welt, MD
Contact
tobias.welt@pukzh.ch
0041 58 389 93 40
Sebastian Olbrich, Prof. Dr. med.
Contact
sebastian.olbrich@pukzh.ch
0041 58 384 26 37
Sebastian Olbrich, Prof. Dr. med.
study director · Psychiatrische Universitätsklinik Zürich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion